Increased levels of blood platelet‐activating factor (PAF) and PAF‐like lipids in patients with ischemic stroke

Acta Neurologica Scandinavica

Volumn 85, Issue 2, 1992, Pages 122-127

  Satoh, K ^a   Imaizumi, T ^a   Yoshida, H ^a   Hiramoto, M ^a   Takamatsu, S ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

cerebral thrombosis; PAF like lipids; platelet activating factor (PAF); PMN aggregation; radioimmunoassay

Indexed keywords

THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; STROKE;

AGED; CEREBRAL INFARCTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; PHOSPHOLIPIDS; PLATELET ACTIVATING FACTOR; RADIOIMMUNOASSAY;

EID: 0026501067     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1992.tb04010.x     Document Type: Article

References (35)

1. Platelet‐activating factor
2. Platelet‐activating factor and related acetylated lipids as potent biologically active cellular mediators
3. Neuroregulatory and neuro‐pathological actions of the ether‐phospholipid platelet‐activating factor
4. The de novo biosynthesis of platelet‐activating factor in rat brain
5. Production of platelet‐activating factor from rat cerebellar granule cells in culture
6. Evidence for platelet‐activating factor as a novel mediator in experimental stroke in rabbits
7. Platelet‐activating factor. A putative mediator in central nervous system injury
8. Highly sensitive gas chromatographic‐mass spectrometric method for the determination of platelet‐activating factor in human blood
9. Capillary gas chromatography and tandem mass spectrometry of paf‐acether and analogs: absence of 1‐O‐alkyl‐2‐propionyl‐sn‐glycero‐3‐phosphocholine in human polymorphonuclear neutrophils
10. Platelet‐activating factor. Isolation, identification, and assay
11. Examination for platelet‐activating factor production by preimplantation mouse embryo using a specific radioimmunoassay
12. Development of a novel scintillation proximity radioimmunoassay for platelet‐activating factor measurement: comparison with bioassay and GC/MS techniques
13. Complement(C5a)‐induced granulocyte aggregation in vitro. A possible mechanism of complement‐mediated leukostasis and leukopenia
14. Human endothelial cells in culture produce platelet‐activating factor (1‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine) when stimulated with thrombin
15. Effect of cigarette smoking on the levels of platelet‐activating factor‐like lipid(s) in plasma lipoproteins
16. Biosynthesis of platelet‐activating factor in rabbit polymorphonuclear neutrophils
17. Isolation of mononuclear cells and granulocytes from human blood
18. CV‐3988 ‐ a specific antagonist of platelet‐activating factor (PAF)
19. Existence of endogenous inhibitors of platelet‐activating factor (PAF) with PAF in rat uterus
20. Human endothelial cells in culture produce platelet‐activating factor (1‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine) when stimulated with thrombin
21. The release of platelet‐activating factor from human endothelial cells in culture
22. Cultured endothelial cells synthesize both plateletactivating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate
23. Regulation of PAF‐acether (platelet‐activating factor) biosynthesis in cultured human vascular endothelial cells stimulated with thrombin
24. Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro
25. Molecular species of platelet‐activating factor generated by human neutrophils challenged with ionophore A23187
26. The intracellular retention of newly synthesized platelet‐activating factor
27. An oxidized derivative of phosphatidylcholine is a substrate for the platelet‐activating factor acetylhydrolase from human plasma
28. Platelet‐activating factor‐like lipid in oxidizea low density lipoprotein
29. Serum lipid peroxides in cerebrovascular disorders determined by a new colorimetric method
30. Plasma thiobarbituric acid reactive substances are a predictive marker of cerebral ischemia in patients at high risk
31. Activity of platelet‐activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular disease
32. Increased activity of the platelet‐activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension
33. Platelet‐activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2